Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Clinical Study of PD-1 Monoclonal Antibody (Sintilimab) Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma/ Esophagogastric Junction Adenocarcinoma

Next Previous
Trial Profile

Phase II Clinical Study of PD-1 Monoclonal Antibody (Sintilimab) Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma/ Esophagogastric Junction Adenocarcinoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Calcium (Primary) ; Capecitabine (Primary) ; Docetaxel (Primary) ; Fluorouracil (Primary) ; Oxaliplatin (Primary) ; Sintilimab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 17 Jan 2021 Results (n=20) presented at the 2021 Gastrointestinal Cancers Symposium
  • 04 Nov 2020 According to an Innovent Biologics media release, Suxia Luo is the principal investigator of this study.
  • 04 Nov 2020 According to an Innovent Biologics media release, data from this study will be presented during the upcoming European Society of Medical Oncology ASIA ("ESMO ASIA") Virtual Congress 2020 from November 20th to 22nd.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top